Thursday, 18 October 2018 01:03

Appendix 4G and Corporate Governance Statement

Download attachments: Download PDF

 
Thursday, 18 October 2018 01:00

Notice of Annual General Meeting/Proxy Form

Download attachments: Download PDF

 
Wednesday, 10 October 2018 07:15

Appeal Upheld Against NICE Recommendation in England

APPEAL UPHELD AGAINST NICE RECOMMENDATION IN ENGLAND Appeal Panel remits to NICE evaluation committee to readdress the assessment underlying the reimbursement of SCENESSE® for the treatment of English EPP patients Melbourne, Australia and Leatherhead, UK, 10 October 2018 CLINUVEL PHARMACEUTICALS LTD today announced that the Appeal Panel of the National Institute of Health and Care […]

 
Monday, 08 October 2018 08:19

Sachs 18th Biotech in Europe Forum Presentation

Download attachments: 20181008_Sachs_Biotech_Europe_Forum_Presentation.pdf

 
Friday, 05 October 2018 07:19

Chair Letter to Shareholders

Download attachments: 20181005_Chair_Letter.pdf

 
Thursday, 04 October 2018 06:32

Ceasing to be a substantial holder

Download attachments: 20181004_Form605_Lagoda.pdf

 
Wednesday, 03 October 2018 05:33

CLINUVEL Confirms AGM Date

CLINUVEL CONFIRMS AGM DATE Melbourne, Australia, 3 October 2018 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY) today announced it will hold its 2018 Annual General Meeting of shareholders on Wednesday 21 November 2018 at 10.00am AEDT at The Events Centre at Collins Square, Tower 2, Level 6, 727 Collins Street, Melbourne, […]

 

CLINUVEL INITIATES VARIEGATE PORPHYRIA PROOF OF CONCEPT STUDY SCENESSE® to be clinically evaluated in second cutaneous porphyria Melbourne, Australia, 01 October 2018 EXECUTIVE SUMMARY Proof of concept Phase IIa study in genetic metabolic disorder variegate porphyria (VP) Six patients evaluated following up to six doses of SCENESSE® in 2019 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: […]

 

Download attachments: Download PDF

 
Tuesday, 11 September 2018 07:06

Appendix 3B

Appendix 3B Download attachments: Download PDF

 
Monday, 10 September 2018 07:45

Investor Presentation NewsMakers Conference

Download attachments: 20180910_InvestorPresentationNewsMakersConference.pdf

 
Wednesday, 05 September 2018 07:23

US FDA Update

US FDA UPDATE Agency requests additional information on SCENESSE® new drug application for the treatment of EPP Melbourne, Australia, and New York, USA, 05 September 2018 EXECUTIVE SUMMARY FDA requests further documentation as part of the new drug application (NDA) Decision on Priority Review will be made following satisfaction of all agency requests CLINUVEL PHARMACEUTICALS […]

 
Tuesday, 04 September 2018 10:03

Change in substantial holding

Download attachments: 20180904Form604_FIL.pdf

 
Wednesday, 29 August 2018 07:00

Notification of dividend / distribution

Download attachments: Download PDF

 
Wednesday, 29 August 2018 06:48

CLINUVEL declares first time dividend

Directors declare dividend upon achieving consecutive years of profit CLINUVEL Group to declare maiden unfranked dividend of A$0.02 per ordinary share following financial results for the year ending 30 June 2018 Record date: 24 September 2018 Ex-Dividend date: 21 September 2018 Payment date: 8 October 2018 Dividend policy to be reported by 30 June 2019 […]